Inline with recentclinical trials demonstrating that ondansetron,a 5-HT3 receptor (5-HT3R) antagonist, amelioratescognitive deficits of schizophrenia and the known procognitive effectsof 5-HT6 receptor (5-HT6R) antagonists, we appliedthe hybridization strategy to design dual-acting 5-HT3/5-HT6R antagonists. This evidence concerns the gene HTR3A and schizophrenia.